CN115916336A - 大麻二酚的组合物和治疗用途 - Google Patents

大麻二酚的组合物和治疗用途 Download PDF

Info

Publication number
CN115916336A
CN115916336A CN202180029644.1A CN202180029644A CN115916336A CN 115916336 A CN115916336 A CN 115916336A CN 202180029644 A CN202180029644 A CN 202180029644A CN 115916336 A CN115916336 A CN 115916336A
Authority
CN
China
Prior art keywords
cannabidiol
pharmaceutical composition
gating
syndrome
long
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180029644.1A
Other languages
English (en)
Chinese (zh)
Inventor
马尼特·帕特尔
彼得·查尔斯·鲁本
穆罕默德·阿明·福达
穆罕默德-礼萨·焦万诺
维沙尔·阿南特·贾达夫
达纳·A·帕杰
库希克·乔杜里
鲁西诺娃·拉达
特亚斯·法特佩卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shrima Machant
Original Assignee
Shrima Machant
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shrima Machant filed Critical Shrima Machant
Publication of CN115916336A publication Critical patent/CN115916336A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180029644.1A 2020-02-19 2021-02-19 大麻二酚的组合物和治疗用途 Pending CN115916336A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN202021007184 2020-02-19
IN202021007184 2020-02-19
IN202021013770 2020-03-29
IN202021013770 2020-03-29
PCT/IN2021/050159 WO2021165992A1 (en) 2020-02-19 2021-02-19 Compositions and therapeutic uses of cannabidiol

Publications (1)

Publication Number Publication Date
CN115916336A true CN115916336A (zh) 2023-04-04

Family

ID=77391770

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180029644.1A Pending CN115916336A (zh) 2020-02-19 2021-02-19 大麻二酚的组合物和治疗用途

Country Status (9)

Country Link
US (1) US20230123654A1 (https=)
EP (1) EP4106870A4 (https=)
JP (1) JP2023516284A (https=)
CN (1) CN115916336A (https=)
AU (1) AU2021223191A1 (https=)
CA (1) CA3171890A1 (https=)
IL (1) IL295753A (https=)
WO (1) WO2021165992A1 (https=)
ZA (1) ZA202210355B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296892A (en) * 2020-03-29 2022-12-01 Akseera Pharma Corp Interaction of sars-cov-2 proteins through a molecular or cellular mechanism of host cells and compounds for the treatment of covid -19
AU2021250462A1 (en) * 2020-04-02 2022-12-01 Incannex Healthcare Limited Methods and compositions for treating or preventing an inflammatory condition
WO2022122904A1 (en) * 2020-12-09 2022-06-16 Chanelle Mccoy Cbd Limited A delayed-release capsule of cannabidiol
AU2022204290A1 (en) * 2020-12-12 2023-07-27 Akseera Pharma Corp. Cannabidiol for augmenting vaccine mediated immunity and prophylaxis of covid-19
IL309886A (en) * 2021-07-15 2024-03-01 Incannex Healthcare Ltd A preparation containing cannabidiol and hydroxychloroquine in a combined capsule at a fixed dose
JPWO2024043242A1 (https=) * 2022-08-23 2024-02-29

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265788A1 (en) * 2003-06-26 2004-12-30 Sho-Ya Wang Screen for sodium channel modulators
WO2017178937A1 (en) * 2016-04-13 2017-10-19 Uab Satimed The oleo gel composition and delivery system with active compounds from cannabis sativa and mentha arvensis for reduction of inflammation and pain in deep tissues
CN108079305A (zh) * 2016-11-23 2018-05-29 汉义生物科技（北京）有限公司 大麻二酚与三环类抗抑郁药的药物组合物及其用途
CN109414443A (zh) * 2016-05-02 2019-03-01 斯特罗生物技术公司 用于降低类固醇剂量并治疗炎性和自身免疫性疾病的大麻二酚
WO2019113685A1 (en) * 2017-12-12 2019-06-20 Cardiol Therapeutics Inc. Amphiphilic block copolymers, micelles, and methods for treating or preventing heart failure
WO2019140357A1 (en) * 2018-01-13 2019-07-18 Truetiva Inc. Anti-aging and skin tone lightening compositions and methods for same
CN110575448A (zh) * 2018-06-08 2019-12-17 云南汉素生物科技有限公司 大麻二酚组合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX376077B (es) * 2013-03-13 2025-03-07 Univ Cincinnati Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2.
WO2016161138A1 (en) * 2015-03-31 2016-10-06 Stamets Paul Edward Antiviral activity from medicinal mushrooms and their active constituents
AU2018273410A1 (en) * 2017-05-26 2020-01-16 Altum Pharmaceuticals Inc. Biphasix cannabinoid delivery
WO2020183456A1 (en) * 2019-03-10 2020-09-17 Bol Pharma Ltd. Cannabinoid combinations for treating chronic pain in dialysis patients

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265788A1 (en) * 2003-06-26 2004-12-30 Sho-Ya Wang Screen for sodium channel modulators
WO2017178937A1 (en) * 2016-04-13 2017-10-19 Uab Satimed The oleo gel composition and delivery system with active compounds from cannabis sativa and mentha arvensis for reduction of inflammation and pain in deep tissues
CN109414443A (zh) * 2016-05-02 2019-03-01 斯特罗生物技术公司 用于降低类固醇剂量并治疗炎性和自身免疫性疾病的大麻二酚
CN108079305A (zh) * 2016-11-23 2018-05-29 汉义生物科技（北京）有限公司 大麻二酚与三环类抗抑郁药的药物组合物及其用途
WO2019113685A1 (en) * 2017-12-12 2019-06-20 Cardiol Therapeutics Inc. Amphiphilic block copolymers, micelles, and methods for treating or preventing heart failure
WO2019140357A1 (en) * 2018-01-13 2019-07-18 Truetiva Inc. Anti-aging and skin tone lightening compositions and methods for same
CN110575448A (zh) * 2018-06-08 2019-12-17 云南汉素生物科技有限公司 大麻二酚组合物及其用途

Also Published As

Publication number Publication date
AU2021223191A1 (en) 2022-10-13
IL295753A (en) 2022-10-01
JP2023516284A (ja) 2023-04-19
US20230123654A1 (en) 2023-04-20
WO2021165992A1 (en) 2021-08-26
EP4106870A4 (en) 2024-04-10
EP4106870A1 (en) 2022-12-28
CA3171890A1 (en) 2021-08-26
ZA202210355B (en) 2024-02-28

Similar Documents

Publication Publication Date Title
CN115916336A (zh) 大麻二酚的组合物和治疗用途
US10357458B2 (en) Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
US8802702B2 (en) Compounds for reducing drug resistance and uses thereof
JP2024095746A (ja) 心筋ｉｋｒチャネルの薬剤誘発性阻害のリポソームによる軽減
US10349884B2 (en) Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
EP3960158B1 (en) Amlodipine formulations
US20140378521A1 (en) Use of nk-1 receptor antagonists in pruritus
ES2773834T3 (es) Métodos y composiciones para tratar la depresión usando ciclobenzaprina
CN104703603A (zh) 新用途
CA3144983A1 (en) Treatment of pain using allosteric modulator of trpv1
CA3145824A1 (en) System for enhancing therapeutic compliance of the anti-cancer compound e7766
KR20240012533A (ko) 자가면역, 동종면역, 염증성 및 미토콘드리아 질환 치료용 조성물 및 이의 용도
US11071731B2 (en) Allosteric modulators of the mu opioid receptor
US12004868B2 (en) Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
WO2022247834A1 (zh) 一种抗抑郁和抗焦虑的取代桂皮酰胺化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230404

WD01 Invention patent application deemed withdrawn after publication